HETEROCYCLIC IMMUNOMODULATORS AS INHIBITOR OF IMMUNE RESPONSE CHECKPOINTS PDL1 Russian patent published in 2024 - IPC C07D405/04 C07D405/14 A61K31/4433 A61K31/4439 A61K31/444 A61P31/18 A61P31/20 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I), including stereoisomers or tautomeric forms thereof, or a pharmaceutically acceptable salt thereof. In formula (I): R¹ is represented by formula (g-1), R², R³, R⁴, R⁵, R⁷ and R¹¹ are H; R⁶ is selected from H, halogen, C_1-4alkyl and C_1-4alkyl substituted with one or more F atoms; R⁸ and R⁹ are independently selected from H and C_1-6alkyl, wherein each of C_1-6alkyl is optionally substituted with one or more substitutes selected from C_1-4alkyl, OH, OCH₃, -CO₂H, -CO₂C_1-4alkyl and C_3-6heterocycle containing one heteroatom N, where C_3-6heterocycle is optionally substituted with one or more substitutes selected from oxo; provided that R⁸ and R⁹ do not simultaneously represent H; or where R⁸ and R⁹ are joined together to form a C_3-6heterocycle containing one N heteroatom, optionally substituted with one or more substitutes selected from OH and CO₂H; R¹⁰ is selected from H, CN, halogen and heteroaryl containing three N heteroatoms; X is N or CR¹²; R¹² is selected from H, F, Cl, CN. Also disclosed is a method of producing said compound and a pharmaceutical composition containing said compound.

EFFECT: disclosed compounds are PD-L1 inhibitors and can be used in treating infectious diseases and cancer.

22 cl, 2 tbl, 3 ex